791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)
- Resource Type
- article
- Source
- Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
- Subject
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 - Language
- English
- ISSN
- 2051-1426